ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced ...
WHIPPANY, N.J.--(BUSINESS WIRE)--May 30, 2026-- Primary results from the Phase II ARACOG (AFT-47) trial, a head-to-head randomized trial conducted by Alliance Foundation Trials LLC, showed that patients treated with NUBEQA ® (darolutamide; n=55) …